BioLineRx Receives Notice of Allowance from USPTO

BioLineRx

announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia. The patent, when granted, will be valid at least until 2031, without taking into account any possible extension periods, which is nine years longer than the granted patent coverage previously reported by the Company. Corresponding patent applications are pending in Europe, Japan, India, China, Brazil, Mexico, Canada, Australia and Israel. "We are extremely pleased with the allowance of the patent covering BL-1020's crystalline form by the USPTO. There is now a significantly